Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Suramin's development: what did we learn?

Maninderjeet Kaur1, Eddie Reed, Oliver Sartor

  • 1Molecular Pharmacology Section, Cancer Therapeutic Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA.

Investigational New Drugs
|July 9, 2002
PubMed
Summary

Suramin showed initial promise for prostate cancer but later studies revealed only modest palliative effects due to confounding factors. Its development provided valuable lessons for hormone-refractory prostate cancer trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardized template for clinical reporting of PSMA PET/CT scans.

European journal of nuclear medicine and molecular imaging·2024
Same author

Neurologic Symptoms After <sup>177</sup>Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2024
Same author

Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer <sup>177</sup>Lu-PSMA-617 therapy.

Frontiers in oncology·2024
Same author

Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.

Cancer·2024
Same author

Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].

European urology·2024
Same author

BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression.

Journal of the National Cancer Institute·2024

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Suramin, a polysulphonated napthylurea, was investigated for anticancer properties, particularly in prostate cancer.
  • Early studies reported high response rates, suggesting potential efficacy.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of suramin in prostate cancer treatment.
  • To understand the confounding variables affecting early clinical results.
  • To identify lessons learned from suramin's development for future prostate cancer trials.

Main Methods:

  • Review of early clinical results and a recent double-blind study.
  • Analysis of confounding variables including antiandrogen withdrawal and hydrocortisone use.
  • Assessment of suramin's toxicity profile and dose-response relationship.

Related Experiment Videos

Main Results:

  • Early promising results were likely influenced by confounding variables.
  • A recent double-blind study indicated only modest palliative effects in androgen-independent prostate cancer.
  • Suramin exhibits numerous reversible toxicities, with neurotoxicity being a significant concern related to dosing intensity.

Conclusions:

  • Suramin has a low therapeutic index and significant toxicities for prostate cancer treatment.
  • Lessons from suramin's development, such as recognizing anti-androgen withdrawal and utilizing PSA, have advanced prostate cancer research.
  • Further research is needed to optimize treatment strategies for hormone-refractory prostate cancer.